WK Kellogg revenue beats analyst estimates
By Steve Gelsi
Cereal giant says margins grew wider
WK Kellogg Co. said its first-quarter profit rose by about 38%, while revenue beat the analyst estimates, but its stock cooled off after gains in recent weeks.
WK Kellogg (KLG) said its profit increased to $33 million, or 37 cents a share, from $24 million, or 28 cents a share, in the year-ago quarter.
The Battle Creek, Mich.-based food giant matched the FactSet consensus estimate of 37 cents a share.
Revenue fell by 1.9% to $707 million, beating the analyst estimate of $697.8 million.
The company's reported net income margin rose to 4.7% from 3.3%.
WK Kellogg continues to expect 2024 adjusted net sales growth of negative 1% to positive 1%.
WK Kellogg's stock fell 1.1% on Tuesday, giving back some of its recent gains including a 15.6% rise in the past month.
WK Kellogg's stock is up 79% so far in 2024, compared to an 8.6% gain in the S&P 500 .
In October, the former Kellogg Co. separated its North American cereal business through a tax-free spin-off of WK Kellogg Co. to its shareholders.
It also spun off snack food specialist Kellanova (K), which reported its latest quarterly results last week.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-07-24 1025ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks